- Home
- ACVA vs FOLD Comparison
ACVA vs FOLD Comparison
Compare ACVA & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACVA
- FOLD
- Stock Information
- Founded
- ACVA 2014
- FOLD 2002
- Country
- ACVA United States
- FOLD United States
- Employees
- ACVA N/A
- FOLD N/A
- Industry
- ACVA Business Services
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- ACVA Consumer Discretionary
- FOLD Health Care
- Exchange
- ACVA Nasdaq
- FOLD Nasdaq
- Market Cap
- ACVA 2.5B
- FOLD 2.9B
- IPO Year
- ACVA 2021
- FOLD 2007
- Fundamental
- Price
- ACVA $14.31
- FOLD $6.83
- Analyst Decision
- ACVA Strong Buy
- FOLD Strong Buy
- Analyst Count
- ACVA 11
- FOLD 9
- Target Price
- ACVA $22.73
- FOLD $17.00
- AVG Volume (30 Days)
- ACVA 2.9M
- FOLD 3.9M
- Earning Date
- ACVA 05-07-2025
- FOLD 05-08-2025
- Dividend Yield
- ACVA N/A
- FOLD N/A
- EPS Growth
- ACVA N/A
- FOLD N/A
- EPS
- ACVA N/A
- FOLD N/A
- Revenue
- ACVA $637,156,000.00
- FOLD $528,294,999.00
- Revenue This Year
- ACVA $23.93
- FOLD $21.83
- Revenue Next Year
- ACVA $23.63
- FOLD $22.16
- P/E Ratio
- ACVA N/A
- FOLD N/A
- Revenue Growth
- ACVA 32.40
- FOLD 32.29
- 52 Week Low
- ACVA $11.88
- FOLD $6.20
- 52 Week High
- ACVA $23.46
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- ACVA 46.94
- FOLD 32.01
- Support Level
- ACVA $13.76
- FOLD $6.20
- Resistance Level
- ACVA $14.71
- FOLD $6.95
- Average True Range (ATR)
- ACVA 1.04
- FOLD 0.43
- MACD
- ACVA 0.16
- FOLD -0.04
- Stochastic Oscillator
- ACVA 68.07
- FOLD 29.86
About ACVA ACV Auctions Inc.
ACV Auctions Inc is a mobile platform for wholesale car auctions. The company provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.